The Cleveland Clinic
The PhotonBlade 3 Smoke Evacuation device is a monopolar RF device coupled with illumination that is FDA approved and indicated for cutting and coagulation of soft tissue during surgical procedures and for removing smoke generated by electrosurgery when used in conjunction with an effective smoke evacuation system. The device includes a coated electrode at the distal end of a rotatable and extendable shaft (telescope) which delivers monopolar radiofrequency energy for cutting and coagulation of tissue. These devices enable the operator to remotely conduct an electrosurgical current from the output connector of an electrosurgical unit (ESU) to the operative site for the desired surgical effect. The integrated LED-based illumination allows the user to turn on or off the illumination. The integrated smoke evacuation tubing enables the user to evacuate smoke generated by electrosurgery when used in conjunction with an effective smoke evacuation system. The Photon Blade 3 integrates localized surgical field illumination, simultaneous electrosurgical dissection, and active smoke evacuation. By improving visualization at the point of dissection and reducing smoke plume accumulation, surgeons perform more precise tissue dissection and hemostasis. The Photon Blade 3 device is FDA approved and being used in standard clinical care at Cleveland Clinic per its intended use. Utilization of the Photon Blade 3 expands feasibility of hidden scar lumpectomy approaches without compromising tissue handling. Cosmetic outcome after lumpectomy significantly influences patient satisfaction, body image, and quality of life. Reduced tissue trauma, optimized hemostasis, and improved control of the resection cavity translate into preservation of native breast contour, potentially leading to lower incidence of fat necrosis with less thermal injury, and more discrete scar placement. The overall goal of this study is to assess the clinical performance and safety of the Photon Blade 3 illuminated electrosurgical device with integrated smoke evacuation, including patient reported outcomes, incorporation of oncoplastic techniques, and surgical field optimization. This study allows for the collection of data from cases where the device is already being used in standard clinical care in accordance with its FDA approved indication.
Inclusion Criteria: * any adult patient (18 years of age or older) undergoing lumpectomy for benign or atypical disease with PI as surgeon at Avon or Fairview Hospital Exclusion Criteria: * Malignancy